|
Report Date : |
01.01.2015 |
IDENTIFICATION DETAILS
|
Name : |
LABORATORIOS EUROMED CHILE S.A. |
|
|
|
|
Registered Office : |
Camino a melipila 7073 Cerrillos Santiago |
|
|
|
|
Country : |
Chile |
|
|
|
|
Date of Incorporation : |
01.01.1993 |
|
|
|
|
Legal Form : |
Public company |
|
|
|
|
Line of Business : |
Manufacture of pharmaceutical products, chemicals |
|
|
|
|
No. of Employee : |
60 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
USD 100 000 |
|
|
|
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30, 2014
|
Country Name |
Previous Rating (30.06.2014) |
Current Rating (30.09.2014) |
|
Chile |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
CHILE ECONOMIC OVERVIEW
Chile has a market-oriented economy characterized by a high level of foreign trade and a reputation for strong financial institutions and sound policy that have given it the strongest sovereign bond rating in South America. Exports of goods and services account for approximately one-third of GDP, with commodities making up some three-quarters of total exports. Copper alone provides 19% of government revenue. From 2003 through 2013, real growth averaged almost 5% per year, despite the slight contraction in 2009 that resulted from the global financial crisis. Chile deepened its longstanding commitment to trade liberalization with the signing of a free trade agreement with the US, which took effect on 1 January 2004. Chile has 22 trade agreements covering 60 countries including agreements with the European Union, Mercosur, China, India, South Korea, and Mexico. Chile has joined the United States and nine other countries in negotiating the Trans-Pacific-Partnership trade agreement. The Chilean Government has generally followed a countercyclical fiscal policy, accumulating surpluses in sovereign wealth funds during periods of high copper prices and economic growth, and generally allowing deficit spending only during periods of low copper prices and growth. As of 31 December 2012, those sovereign wealth funds - kept mostly outside the country and separate from Central Bank reserves - amounted to more than $20.9 billion. Chile used these funds to finance fiscal stimulus packages during the 2009 economic downturn. In May 2010 Chile signed the OECD Convention, becoming the first South American country to join the OECD.
|
Source
: CIA |
|
Order: |
Laboratorios Euromed Chile S.A |
|
Address in the order: |
Tax Payers ID#: 79.802.770-0
Camino a melipila 7073 Cerrillos Santiago, Chile |
|
Legal Name: |
LABORATORIOS EUROMED CHILE S.A. |
|
Trade Name: |
EUROMED |
|
RUC: |
79802770-0 |
|
Date Created: |
1972 |
|
Date Incorporated: |
01-01-1993 |
|
Legal Address: |
Camino
a melipila 7073 Cerrillos Santiago, Chile |
|
Operative Address: |
Camino
a melipila 7073 Cerrillos Santiago, Chile |
|
Telephone: |
56
2 2483 1602 |
|
Fax: |
56
2 2483 1602 |
|
Legal Form: |
Sociedad
Anónima |
|
Email: |
|
|
Registered in: |
Chile |
|
Website: |
|
|
Manager: |
JAIME
SALAMÉ SABJA |
|
Staff: |
60 |
|
Activity: |
MANUFACTURE OF PHARMACEUTICAL PRODUCTS,
CHEMICALS |
Santander Río
The company does not make its banking data public
Euromed Laboratorios Chile SA is a Pharmaceutical Company Brazilian capitals with 42 years of experience.
Continuing its goal of internationalization in 2010 Eurofarma acquired Laboratorios Gautier de Uruguay, with a presence also in Bolivia. In the same year, joins Volta and Farmindustria, companies of the same group in Chile creating Laboratorios Chile SA Euromed.
Maurizio Billi, the majority shareholder of the third-largest Brazilian drug producer, Eurofarma Laboratorios Ltda, has amassed a fortune worth more than 1.2 billion, while Ache Laboratorios Farmaceuticos SA, a Sao Paulo-based company that had sales of 1.9 billion Reais in 2013, has made billionaire fortunes for its three major shareholders, the Depieri, Baptista and Siaulys families.
Eurofarma and EMS are surpassed in scale by Laboratorio Neo Quimica, the
pharmaceutical unit of consumer goods company Hypermarcas SA, which had revenue
of 2.3 billion Reais last year.
The two companies are the second- and third-biggest producers of sildenafil
citrate pills in Brazil, trailed by Pfizer in sixth place, according to IMS
Health.
EMS exports to more than 40 countries in Latin America, Europe, Africa and
Asia.
Euromed Chile has a pharmaceutical plant and other dietary supplements, equivalent to 7,500 m2 built on a plot of 22,000 m2. The product quality is guaranteed by certified GMP (Good Manufacturing Practices) of the Chilean Institute of Public Health, certification and qualification CENABAST providers of health authorities and environmental and non polluting industry.
|
Products/Services description: |
The subsidiary has 200 drugs
and acts focused in the areas of Medical Prescription, generic and hospital
products, and manufacturing for third parties. |
|
Brands: |
EUROFARMA - EUROMED |
|
Sales are: |
Wholesale |
|
Clients: |
CENTRAL DE ABASTECIMIENTOS(CENABAST), HOSPITAL BARROS LUCO, JUNAEB,
CONASIDA, CONSEJO DE LAS AMERICAS |
|
Suppliers: |
Constantia Hueck |
|
Operations area: |
National |
|
The company imports from |
Colombia, India, Germany and
Malaysia. |
|
The company exports to |
No exports data |
|
The subject employs |
60 employees |
|
Payments: |
Regular |
|
Headquarters : |
Camino
a melipila 7073 Cerrillos Santiago, Chile |
|
Branches: |
The company does not have
branches |
|
Industry: |
|
|
Listed at the stock exchange: |
NO |
|
Capital: |
NA |
|
Shareholders %: |
This
is a private company. Its shareholder is: |
|
Management: |
JAIME SALAMÉ SABJA -
Manager |
|
Sisters: |
Eurofarma Argentina |
This is a private company which does not make its financial figures public.
Despite our long search, we could not confirm financial data.
|
Eurofarma Laboratórios S.A. (PARENT) |
|
|
2013 |
|
|
Revenue |
R$2 Billion |
|
Cash Flow |
Good |
There are no legal/criminal connected to the subject
|
Requested Credit Amount |
Maximum |
|
Maximum Credit Provided |
USD 100 000 |
Euromed Chile has a
pharmaceutical plant and other dietary supplements.
The company is the result of a joint between Volta and Farmindustria. It was
acquired by Eurofamr Brazil.
There are no negtaive connected to the subject.
It is involved in several commercial transactions with the Chilean Municipality
and Ministry.
|
DEBTS |
Controlled |
|
PAYMENTS |
Regular |
|
CASH FLOW |
Normal |
|
SUGGESTED CREDIT LINE |
USD 100 000 |
|
STATUS |
Active |
|
NAME |
Gabriella |
|
POSITION |
Sales |
|
COMMENTS |
She confirmed address and
manager. She refused to provide us with more data. |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.63.33 |
|
|
1 |
Rs.98.58 |
|
Euro |
1 |
Rs.77.00 |
INFORMATION DETAILS
|
Analysis Done by
: |
SUB |
|
|
|
|
Report Prepared
by : |
DPT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall
operation is considered normal. Capable to meet normal commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s
credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or
its officials.